EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Open Access · CC BY 4.0

A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia

Pau Montesinos iD, Vamsi Kota, Joseph Brandwein, Pierre Bousset, Rebecca J Benner, Erik Vandendries, Ying Chen, Mary Frances McMullin

Cancer Chemotherapy and Pharmacology · 2023

DOI: 10.1007/s00280-023-04516-9 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2023. Verfasst von Pau Montesinos und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hospital Universitario y Politècnico La Fe, Avda. Fernando Abril Martorell, 106-Torre A, 4º planta, 46026, Valencia, Spain.…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Gemtuzumab ozogamicin (GO) is indicated for treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML). The QT interval, pharmacokinetics (PK), and immunogenicity following the fractionated GO dosing regimen have not been previously assessed. This phase IV study was designed to obtain this information in patients with R/R AML.

Methods

Patients aged ≥ 18 years with R/R AML received the fractionated dosing regimen of GO 3 mg/m 2 on Days 1, 4, and 7 of each cycle, up to 2 cycles. The primary endpoint was mean change from baseline in QT interval corrected for heart rate (QTc).

Results

Fifty patients received ≥ 1 dose of GO during Cycle 1. The upper limit of the 2-sided 90% confidence interval for least squares mean differences in QTc using Fridericia’s formula (QTcF) was < 10 ms for all time points during Cycle 1. No patients had a post-baseline QTcF > 480 ms or a change from baseline > 60 ms. Treatment-emergent adverse events (TEAEs) occurred in 98% of patients; 54% were grade 3–4. The most common grade 3–4 TEAEs were febrile neutropenia (36%) and thrombocytopenia (18%). The PK profiles of both conjugated and unconjugated calicheamicin mirror that of total hP67.6 antibody. The incidence of antidrug antibodies (ADAs) and neutralizing antibodies was 12% and 2%, respectively.

Conclusion

Fractionated GO dosing regimen (3 mg/m 2 /dose) is not predicted to pose a clinically significant safety risk for QT interval prolongation in patients with R/R AML. TEAEs are consistent with GO’s known safety profile, and ADA presence appears unassociated with potential safety issues. Trial registry Clinicaltrials.gov ID: NCT03727750 (November 1, 2018).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHumansGemtuzumabSialic Acid Binding Ig-like Lectin 3CalicheamicinsAminoglycosides

Stichwörter der Autor:innen

AMLGemtuzumab ozogamicinPharmacokineticsPhase IVQT intervalSafety

Substanzen

GemtuzumabSialic Acid Binding Ig-like Lectin 3CalicheamicinsAminoglycosidesCD33 protein, human

Autor:innen und Institutionen

  • Department of Hematology, Hospital Universitario y Politècnico La Fe, Avda. Fernando Abril Martorell, 106-Torre A, 4º planta, 46026, Valencia, Spain. montesinos_pau@gva.es.
  • Department of Medicine: Hematology and Oncology, Medical College of Georgia, Augusta University, Augusta, GA, USA.
  • Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.
  • Pfizer Oncology, Pfizer Inc., Paris, France.
  • Pfizer Oncology, Pfizer Inc., Groton, CT, USA.
  • Pfizer Oncology, Pfizer Inc., Cambridge, MA, USA.

ORCID-Profile: Pau Montesinos

Förderung

  • Pfizer

Zitieren

APA

Montesinos, P., Kota, V., Brandwein, J., Bousset, P., Benner, R. J., Vandendries, E., Chen, Y., & McMullin, M. F. (2023). A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-023-04516-9

Vancouver

Montesinos P, Kota V, Brandwein J, Bousset P, Benner RJ, Vandendries E, et al. A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia. Cancer Chemotherapy and Pharmacology. 2023. doi:10.1007/s00280-023-04516-9

BibTeX
@article{Montesinos2023,
  author = {Montesinos, Pau and Kota, Vamsi and Brandwein, Joseph and Bousset, Pierre and Benner, Rebecca J and Vandendries, Erik and Chen, Ying and McMullin, Mary Frances},
  title = {A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2023},
  doi = {10.1007/s00280-023-04516-9}
}
Kostenlos starten →